martes, 29 de enero de 2013

Clinical utility of the prostate cancer gene 3 (PCA3... [BJU Int. 2013] - PubMed - NCBI

Clinical utility of the prostate cancer gene 3 (PCA3... [BJU Int. 2013] - PubMed - NCBI

BJU Int. 2013 Jan 18. doi: 10.1111/j.1464-410X.2012.11683.x. [Epub ahead of print]

Clinical utility of the prostate cancer gene 3 (PCA3) urine assay in Japanese men undergoing prostate biopsy.

Source

Department of Urology, Kyoto Prefectural University of Medicine, Kyoto.

Abstract

WHAT'S KNOWN ON THE SUBJECT? AND WHAT DOES THE STUDY ADD?: It is known that a prostate cancer gene 3 (PCA3) urine assay is superior to serum PSA level or PSA-related indices for predicting a positive biopsy result in European and US men. This is the first report on PCA3 in a large cohort of Japanese men. The diagnostic value of the PCA3 score in Japanese men was similar to those reported in European and US men. The study concludes that a combination of PSA density and PCA3 score may be useful for selecting patients who could avoid an unnecessary biopsy.

OBJECTIVE:

To examine the diagnostic performance of the prostate cancer gene 3 (PCA3) score for prostate cancer in Japanese men undergoing prostate biopsy.

PATIENTS AND METHODS:

This Japanese, multicentre study included 647 Asian men who underwent extended prostate biopsy with elevated prostate-specific antigen (PSA) and/or abnormal digital rectal examination (DRE). Urine samples were collected after DRE. The PCA3 score was determined using a PROGENSA PCA3 assay and correlated with biopsy outcome. Its diagnostic accuracy was compared with that of serum PSA level, prostate volume (PV), PSA density (PSAD), and free/total PSA ratio (f/t PSA).

RESULTS:

A total of 633 urine samples were successfully analysed (the informative rate was 98%). Median PSA was 7.6 ng/mL. Biopsy revealed cancer in 264 men (41.7%). The PCA3 score for men with prostate cancer was significantly higher than that for men with negative biopsies (median PCA3 score: 49 vs. 18; P < 0.001). The rate of positive biopsy was 16.0% in men with a PCA3 score of <20 0.05="" 0.15="" 0.647="" 20="" 35="" 4-10="" 60.6="" 66.5="" 71.6="" 72="" a="" and="" area="" cancer.="" curve="" f="" had="" higher="" in="" men="" ml="" ng="" of="" only="" out="" p="" pca3="" prostate="" psa="" psad="" respectively.="" score="" sensitivity="" significantly="" specificity="" t="" than="" that="" the="" those="" three="" threshold="" under="" using="" vs="" was="" were="" with="">

CONCLUSIONS:

The PCA3 score was significantly superior to f/t PSA in predicting a positive biopsy result for prostate cancer in Japanese men with PSA 4-10 ng/mL. The combination of PSAD and PCA3 score may be useful for selecting patients who could avoid an unnecessary biopsy.
© 2013 BJU International.

PMID:
23331404
[PubMed - as supplied by publisher]

No hay comentarios:

Publicar un comentario